APJ-compound-14

oral apelin receptor GPCR agonist

completed Ph. I for heart failure, discontinued

from cell-based HTS and opt.

J. Med. Chem., Mar. 19, 2021

Bristol Myers Squibb, Princeton, NJ

The Bristol Myers Squibb apelin receptor (APJ) GPCR agonist (“compound 14”) is a clinical candidate for heart failure which completed a Ph. I study. Endogenous pyroglutamated apelin-13 peptide has…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks